2.9—Next-Gen Drug Discovery Platform with First Immune/Oncology Target Validated

This is a novel approach to fine-tune immune responses by utilizing transposon-derived gene variants, including a newly identified interferon receptor isoform, IFNAR2-S. This breakthrough enables the precise modulation of inflammation and antiviral defense, with significant implications for cancer immunotherapy and the potential to create novel therapeutics that make tumors more visible to the immune system. This innovative strategy has the potential to dramatically improve the effectiveness of immunotherapies, particularly in cancers that currently evade detection. Backed by a recent $1.25 million award, this research opens a bold new frontier in precision oncology.

Inventor: Ed Chuong (CU Boulder BioFrontiers Institute)

Potential Applications: Health and Wellness, Therapeutics, Vaccines, Biotech, Research and Exploration